VOR Vor Biopharma

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA.

Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ET

Location: Regis

A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at:

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:

Carl Mauch

Sarah Spencer



EN
23/02/2026

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and R...

22h / 12m 1 EN
Wedbush Research
  • Wedbush Research
PRGS PROGRESS SOFTWARE CORPORATION
ACRS ACLARIS THERAPEUTICS INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
ANAB ANAPTYSBIO INC.
AAPL APPLE INC.
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
VRDN VIRIDIAN THERAPEUTICS INC
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
TMC THE METALS COMPANY INC
PEPG PEPGEN INC
BCAX BICARA THERAPEUTICS INC.
EIKN EIKON THERAPEUTICS INC
03/31/26 March 31, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
03/30/26 March 30, 2026 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results an...

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoi...

March 30, 2026 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registratio...

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease First and only dual BAFF/APRIL inhibitor in primary Sjögren’s disease, one of the largest autoimmune diseases without an approved therapy BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patient...

March 30, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch